Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Key Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial Reported by Blue Earth Therapeutics

Blue Earth Therapeutics today announced further promising developments for its radiohybrid lutetium labelled, PSMA targeted, investigational radioligand therapy. Radiation dosimetry and pharmacokinetic data from the 13 metastatic castrate...

A convenient and cost-effective way to treat sickle cell disease may be offered by Vascarta's patented transdermal drug candidate

An article in the Proceedings of the National Academy of Sciences (PNAS) Nexus journal* by Goel et al. describes studies in which humanized sickle cell mice topically treated with Vascarta's transdermal curcumin gel formulation ("VAS-101")...

Fosun Pharma deeply embraces AI, with its self-developed PharmAID Decision Intelligence Platform boosting efficient innovation

Nowadays, artificial intelligence (AI) technology is profoundly reshaping the landscape of the pharmaceutical and healthcare industry. As a global innovation-driven pharmaceutical and healthcare group, Fosun Pharma places great emphasis on the...

Harbour BioMed receives NMPA IND clearance for HBM9378/SKB378 in treating chronic obstructive pulmonary disease

Harbour BioMed a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunology, announced that the National Medical Products Administration...

Redefining Pharmaceutical Market Analytics and Insights: PharmaScroll

PharmaScroll, a premier market research and business analytics firm, continues to set the benchmark for excellence in supporting the global life sciences and healthcare organizations. Renowned for its innovative tech-based solutions and in-depth...

Lutris Pharma secures $30 million in financing to advance the development of a biopharmaceutical aimed at improving the effectiveness of anti-cancer drugs

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous dose-limiting toxicity, announced that it has secured a $30 million financing to advance the development of LUT014, an...

Chromatin Bioscience's synthetic promoter enables EsoBiotec's ESO-T01 CAR-T therapy to progress to clinical trials

Chromatin Bioscience is pleased to announce its ongoing collaboration with EsoBiotec, which has successfully advanced its ESO-T01 in vivo CAR-T candidate into clinical trials. ESO-T01 is the first in vivo B-cell maturation antige. (BCMA) CAR-T...

Matthew Fyfe has been appointed as Chief Scientific Officer as Outrun Therapeutics expands its leadership team

Outrun Therapeutics ("Outrun"), the E3 ligase inhibitor and protein stabilisation specialist, announces the appointment of Matthew Fyfe as its Chief Scientific Officer. Matthew has over 25 years' experience in drug discovery and development across...

Ouro Medicines launches to transform treatment for immune-mediated diseases with innovative therapies

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120 million in funding. The company was founded by Monograph Capital in...

RiDYMOยฎ develops a cyclic peptide targeting the "undruggable" ฮฒ-catenin in just two months

In a recent achievement, DP Technology's hit discovery platform RiDYMOยฎ has successfully designed a cyclic peptide targeting ฮฒ-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced...

Axio BioPharma Partners with eMBR Genomics to Manufacture and Distribute Proprietary MKLP1 Proโ„ข Antibodies

In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Proโ„ข antibodies, KIF23 gene โ€“ the same tools used by the world's leading Midbody Remnants (MBRs) researchers. This strategic...

Eden has launched the worldโ€™s first compounded GLP-1 prescription gummy, offering a novel and convenient approach to weight management treatment

Eden has launched the world's first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

UroMems Appoints Former Axonics Executive Rinda Sama to Board of Directors

UroMems, a global medical technology company developing the first smart automated implant to treat stress urinary incontinence (SUI), today announced the appointment of medical device veteran Rinda Sama to its board of directors. "We are thrilled...

Leqembiยฎ approved in Mexico

BioArctic AB's partner Eisai announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer's disease (AD)1. Leqembi selectively binds to...

LEQEMBIยฎ (lecanemab), a treatment for Alzheimer's disease, is now available in South Korea, expanding access to innovative care

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that the humanized anti-soluble aggregated amyloid-beta (Aฮฒ) monoclonal antibody "LEQEMBIยฎ" has...

A Korea University study identifies mitochondrial dysfunction as a key factor in cognitive and metabolic impairments, offering insights into potential treatments

Animal models expressing loss-of-function mutations in mitochondrial DNA enable the investigation of mitochondrial gene function and related disorders. In a recent study, scientists from Korea University described the impact of a mitochondrial ND5...

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

Axonal.AI today unveiled its groundbreaking platform, designed to significantly accelerate speed to market in the life sciences industry. At a time when rapid commercialization is more critical than ever, Axonal.AI's cutting-edge technology...

Bracco Diagnostics Inc. reaches one million injections milestone with its MRI agent, VUEWAYยฎ (gadopiclenol)

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAYยฎ...

Vensica Medical raises $11M to advance Phase 2 trials for its overactive bladder treatment

Vensica Medical a pioneering urology therapeutics company, announced the successful closing of an $11 million funding round. The investment will fund the company's upcoming Phase 2 clinical trials across the United States and Europe for its...